Coherus Biosciences Stock News

Virginia Retirement Systems ET AL reduced its position in Coherus BioSciences, Inc. (NASDAQ:CHRS) by 27.1% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 63,600 shares of the biotechnology companys stock after selling 23,700 shares during the quarter. Virginia Retirement Systems ET ALs holdings in Coherus BioSciences were worth $1,022,000 at the end of the []

Coherus BioSciences Inc. (NASDAQ:CHRS)s traded shares stood at 0.42 million during the last session, with the companys beta value hitting 0.96. At the close of trading, the stocks price was $16.81, to imply a decrease of -1.93% or -$0.33 in intraday trading. The CHRS shares 52-week high remains $22.22, putting it -32.18% down since that Coherus BioSciences Inc. (NASDAQ: CHRS) Has Succeeded In Attracting Investors This Year, The Stock Is Down -3.28% Year-To-Date Read More »

Analysts predict that Coherus BioSciences, Inc. (NASDAQ:CHRS) will report $83.32 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Coherus BioSciences earnings, with the lowest sales estimate coming in at $80.23 million and the highest estimate coming in at $86.40 million. Coherus BioSciences reported sales of $110.42 []

Coherus BioSciences Inc. (NASDAQ:CHRS) concluded the trading at $17.75 on Friday, December 03 with a fall of -1.72% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $18.06 and 5Y monthly beta was reading 0.97 with its price kept floating in the Coherus BioSciences Inc. (CHRS): Sit Tight When Things Go Right Read More »

Key Players covered in the US Biosimilars Market Research Report are Pfizer Inc. (New York, US), Samsung Bioepis (Incheon, South Korea), Celltrion Inc. (Incheon, South Korea), Novartis AG (Basel, Switzerland), Inogen (Goleta, US), Amgen Inc. (California, US), Mylan N.V. (Pennsylvania, US), Coherus BioSciences (California, US), Other Prominent Players Key Players covered in the US Biosimilars Market Research Report are Pfizer Inc. (New York, US), Samsung Bioepis (Incheon, South Korea), Celltrion Inc. (Incheon, South Korea), Novartis AG (Basel, Switzerland), Inogen (Goleta, US), Amgen Inc. (California, US), Mylan N.V. (Pennsylvania, US), Coherus BioSciences (California, US), Other Prominent Players

Coherus BioSciences (NASDAQ:CHRS) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings. Analyst Recommendations This is a breakdown of current ratings for Coherus BioSciences and C4 Therapeutics, []

Metropolitan Life Insurance Co NY lifted its position in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) by 111,231.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,813 shares of the biotechnology companys stock after purchasing an additional 17,797 shares during the period. []

Thrivent Financial for Lutherans boosted its stake in Coherus BioSciences, Inc. (NASDAQ:CHRS) by 3.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 54,496 shares of the biotechnology companys stock after acquiring an additional 1,874 shares during the period. Thrivent Financial []

AQR Capital Management LLC lessened its stake in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) by 75.8% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,007 shares of the biotechnology companys stock after selling 84,533 shares during the period. AQR []

Wall Street analysts expect Coherus BioSciences, Inc. (NASDAQ:CHRS) to post sales of $83.32 million for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Coherus BioSciences earnings, with estimates ranging from $80.23 million to $86.40 million. Coherus BioSciences posted sales of $110.42 million in the same quarter last year, which would []

Charles Schwab Investment Management Inc. boosted its stake in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) by 1.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 475,678 shares of the biotechnology companys stock after acquiring an additional 8,735 shares during the []

Related Stocks: EVH , TLMD , CMAX , EA , CHRS , EXC , GDP , TBT , OAS , CANO , MARA ,

The FDA bestows an Orphan Drug designation to Coherus (CHRS) and partner Junshi's toripalimab for the treatment of esophageal cancer.

REDWOOD CITY, Calif. and SHANGHAI, China, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences, HKEX: 1877; SSE: 688180) announced today that the United States Food and Drug Administration ("FDA") has granted Orphan Drug Designation (ODD) for toripalimab for the treatment of esophageal cancer. Orphan drug designation is granted to drugs and biologics intended to treat rare diseases with a patient population less than 200,000 in the U.S. The designation provides incentives to advance development and commercialization of rare disease drugs.

SHANGHAI, China and REDWOOD CITY, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. (Coherus, Nasdaq: CHRS) announced today that the United States Food and Drug Administration ("FDA") has granted Orphan Drug Designation (ODD) for toripalimab for the treatment of esophageal cancer. Orphan drug designation is granted to drugs and biologics intended to treat rare diseases with a patient population less than 200,000 in the U.S. The designation provides incentives to advance development and commercialization of rare disease drugs.